UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 167

Sortiert nach

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Blood, 2021-02, Vol.137 (6), p.763-774

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector

Molecular therapy, 2012-02, Vol.20 (2), p.443-455

2012

Link zum Volltext

Verfügbarkeit prüfen

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia

Journal of clinical medicine, 2021-06, Vol.10 (11), p.2471

2021

Link zum Volltext

Verfügbarkeit prüfen

Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice

Blood, 2016-07, Vol.128 (2), p.286-292

2016

Link zum Volltext

Verfügbarkeit prüfen

Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune Profiles

Journal of Virology, 2012-08, Vol.86 (15), p.7752-7759

2012

Link zum Volltext

Verfügbarkeit prüfen

Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX

Cell reports (Cambridge), 2018-05, Vol.23 (5), p.1565-1580

2018

Link zum Volltext

Verfügbarkeit prüfen

Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection

Proceedings of the National Academy of Sciences - PNAS, 2009-11, Vol.106 (44), p.18786-18791

2009

Link zum Volltext

Verfügbarkeit prüfen

The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B

Blood advances, 2018-08, Vol.2 (16), p.2136-2144

2018

Link zum Volltext

Verfügbarkeit prüfen

Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical Application

Molecular therapy, 2010-11, Vol.18 (11), p.1907-1916

2010

Link zum Volltext

Verfügbarkeit prüfen

Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose

Molecular therapy, 2008-02, Vol.16 (2), p.280-289

2008

Link zum Volltext

Verfügbarkeit prüfen

Physical Functioning in Boys with Hemophilia in the U.S

American journal of preventive medicine, 2011-12, Vol.41 (6), p.S360-S368

2011

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B

Current medical research and opinion, 2023-02, Vol.39 (2), p.227-237

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Effects of Hemophilia B Gene Therapy. Reply

The New England journal of medicine, 2023-05, Vol.388 (20), p.1918-1919

2023

Link zum Volltext

Verfügbarkeit prüfen

An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs

Molecular therapy. Methods & clinical development, 2018-09, Vol.10, p.257-267

2018

Link zum Volltext

Verfügbarkeit prüfen

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

The New England journal of medicine, 2021-11, Vol.385 (21), p.1961-1973

2021

Link zum Volltext

Verfügbarkeit prüfen

A Translational Study of TNF-Alpha Antagonists as an Adjunctive Therapy for Preventing Hemophilic Arthropathy

Journal of clinical medicine, 2019-12, Vol.9 (1), p.75

2019

Link zum Volltext

Verfügbarkeit prüfen

Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX

Blood, 2008-12, Vol.112 (12), p.4532-4541

2008

Link zum Volltext

Verfügbarkeit prüfen

Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua

Molecular therapy. Methods & clinical development, 2018-09, Vol.10, p.29-37

2018

Link zum Volltext

Verfügbarkeit prüfen

Factor IX: Insights from knock-out and genetically engineered mice

Thrombosis and haemostasis, 2008-10, Vol.100 (4), p.563

Monahan, Paul E

2008

Link zum Volltext

Verfügbarkeit prüfen

Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors

Hematology, 2015-12, Vol.2015 (1), p.33-40

Monahan, Paul E

2015

Link zum Volltext

Verfügbarkeit prüfen

Men with severe hemophilia in the United States: birth cohort analysis of a large national database

Blood, 2016-06, Vol.127 (24), p.3073-3081

2016

Link zum Volltext

Verfügbarkeit prüfen

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-01, Vol.30 (1), p.75-86

2024

Link zum Volltext

Verfügbarkeit prüfen

Discussing investigational AAV gene therapy with hemophilia patients: A guide

Blood reviews, 2021-05, Vol.47, p.100759-100759, Article 100759

2021

Link zum Volltext

Verfügbarkeit prüfen

Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis

Blood, 2017-04, Vol.129 (15), p.2161-2171

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-05, Vol.30 (3), p.709-719

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 167

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(149)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia

Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice

Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune Profiles

Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX

Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection

The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B

Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical Application

Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose

Physical Functioning in Boys with Hemophilia in the U.S

Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B

Long-Term Effects of Hemophilia B Gene Therapy. Reply

An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

A Translational Study of TNF-Alpha Antagonists as an Adjunctive Therapy for Preventing Hemophilic Arthropathy

Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX

Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua

Factor IX: Insights from knock-out and genetically engineered mice

Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors

Men with severe hemophilia in the United States: birth cohort analysis of a large national database

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B

Discussing investigational AAV gene therapy with hemophilia patients: A guide

Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis

Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy

Suchergebnisse filtern